Conmed/$CNMD
1D1W1M3M6MYTD1Y5YMAX
Capital at risk
About Conmed
Conmed Corp is a medical technology company that provides devices and equipment for surgical procedures. The company's products are used by surgeons and other healthcare professionals across specialties, including orthopedics, general surgery, gynecology, thoracic surgery, and gastroenterology. Geographically, the company operates in the United States, Europe, the Middle East & Africa, Asia Pacific, and the Americas, excluding the United States. The majority of revenue is generated from the United States.
- Ticker
- $CNMD
- Sector
- Health
- Primary listing
- NYSE
- Employees
- 3,900
- Headquarters
- Largo, United States
- Website
- www.conmed.com
Conmed Metrics
BasicAdvanced
$1.5B
21.39
$2.41
0.94
-
Price and volume
Market cap
$1.5B
Beta
0.94
52-week high
$54.80
52-week low
$31.44
Average daily volume
414K
Financial strength
Current ratio
1.486
Quick ratio
0.614
Long term debt to equity
0.6
Total debt to equity
0.77
Dividend payout ratio (TTM)
8.43%
Interest coverage (TTM)
3.80%
Profitability
EBITDA (TTM)
214.966
Gross margin (TTM)
54.79%
Net profit margin (TTM)
5.36%
Operating margin (TTM)
10.24%
Effective tax rate (TTM)
30.04%
Revenue per employee (TTM)
$350,000
Management effectiveness
Return on assets (TTM)
3.79%
Return on equity (TTM)
7.10%
Valuation
Price to earnings (TTM)
21.387
Price to revenue (TTM)
1.143
Price to book
1.45
Price to tangible book (TTM)
-5.24
Price to free cash flow (TTM)
11.798
Free cash flow yield (TTM)
8.48%
Free cash flow per share (TTM)
4.365
Growth
Revenue change (TTM)
1.62%
Earnings per share change (TTM)
17.45%
3-year revenue growth (CAGR)
5.43%
10-year revenue growth (CAGR)
6.20%
3-year earnings per share growth (CAGR)
9.09%
10-year earnings per share growth (CAGR)
15.71%
What the Analysts think about Conmed
Analyst ratings (Buy, Hold, Sell) for Conmed stock.
Analyst projections of the future price of Conmed stock.
Bulls say / Bears say
Orthopaedic sales rose 8.2% in the second quarter and 7.5% in the first half, with growth across sports medicine, powered instruments, visualisation and BioBrace. This gives CONMED a solid growth engine outside its exiting gastroenterology products. (SEC)
The expanded indication for AirSeal now covers Intuitive’s da Vinci 5 8 mm hex cannula as well as cannulas used with earlier systems. That broadens compatibility with a key robotic platform and could support further adoption. (Morningstar)
International sales grew 9.9% on an organic constant-currency basis in the second quarter and account for about 45% of sales. Management says newer product launches and approvals, including BioBrace in Brazil, are helping extend that growth runway. (SEC, Investing.com)
Reported sales were almost flat in the second quarter, while the full-year organic constant-currency growth outlook was narrowed to 5%–6% from 5%–6.5%. The gap between underlying growth and reported sales also leaves the headline results exposed to the gastroenterology exit and currency movements. (SEC)
The second-quarter adjusted EPS result included a $0.21 benefit from tariff refunds. Excluding that one-off benefit, adjusted operating income and margin were essentially flat year on year, raising questions about how repeatable the earnings improvement is. (Investing.com)
Operating cash flow fell to $50.6 million in the first half from $70.7 million a year earlier. CONMED also used new term-loan and revolving borrowings to help fund its $645.2 million note repurchase, highlighting the pressure that cash conversion and refinancing can place on financial flexibility. (SEC)
Data summarised monthly by Lightyear AI. Last updated on 19 Oct 2026.
Conmed Financial Performance
Revenues and expenses
Conmed Earnings Performance
Company profitability
Upcoming events
No upcoming events
Conmed News
AllArticlesVideos
Funds containing Conmed
AllUSDEURGBP
Fund name | Fund size | $CNMD weighting |
|---|---|---|
iShares S&P Small Cap 600£ISP6 | $3.2B | 0.09% |
iShares S&P SmallCap 600$IDP6 | $3.2B | 0.09% |
SPDR Russell 2000 US Small Cap€R2US | $5.3B | 0.06% |
SPDR Russell 2000 US Small Cap£R2SC | $5.3B | 0.06% |
SPDR MSCI USA Small Cap Value Weighted$USSC | $1.1B | 0.05% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.